CT:ONC Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol ONCY.
This company has cross-listed shares that trade in the U.S. as the symbol ONCY.
2.35 CAD
As of 02/07/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 01/01/1900
Stock exchange: Toronto Stock Exchange
Exchange country: Canada
Market cap: 77,806,440 CAD
Current dividend yield: 0.00%
Sedol: